Tag: OLN324
-

J&J Agrees to Buy Ollin Biosciences for $2.2 Billion Upfront, Adding OLN324
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront. The deal would add OLN324, a Phase 3 candidate for wet AMD and diabetic macular edema. Early results against Vabysmo highlight differences in retinal imaging and leave open whether OLN324 can preserve vision with fewer injections.